Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months.
ACS Cent Sci
; 9(5): 849-857, 2023 May 24.
Article
em En
| MEDLINE
| ID: mdl-37252346
ABSTRACT
The advancement of nirmatrelvir, the active ingredient in Paxlovid, from discovery to emergency use authorization was achieved in just 17 months, requiring an unprecedented rate of chemical process development.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article